Trial Profile
Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Olesoxime (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms MITOTARGET
- Sponsors Roche; Trophos
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 21 Apr 2016 Results of a retrospective analysis presented at the 68th Annual Meeting of the American Academy of Neurology
- 27 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00868166).